Eli Lilly has agreed to acquire Scorpion Therapeutics’ breast cancer treatment program for up to $2.5 billion in cash. The drugmaker said Monday it is acquiring Scorpion and its STX-478 program ...

Now that the year is underway and a new presidential administration is in place in Washington, let’s consider the environment ...

Eli Lilly & Co. tapped the US investment-grade bond market on Monday to help finance its roughly $2.5 billion purchase of a ...

Eli Lilly has unveiled a $2.5 billion deal to acquire rights to a cancer therapy being developed by Scorpion Therapeutics in a third major transaction announced on the first day of the JP Morgan ...

The company states: “Eli Lilly (LLY) and Scorpion Therapeutics announced a definitive agreement for Lilly to acquire Scorpion’s PI3Kalpha inhibitor program STX-478. STX-478 is a once-daily ...

You have permission to edit this article. Edit Close Activate Subscribe My Account Logout Login/Register ...

Eli Lilly and Co.’s end last year to its PI3Kα inhibitor program didn’t mean the pharma player was giving up on the target – ...

Eli Lilly and RNAi therapeutics specialist OliX Pharmaceuticals have entered into a global licensing agreement to advance a ...

January 2025 kicked off with a wave of impactful biotech deals, setting the stage for an exciting year of innovation.

About Scorpion Therapeutics Scorpion is a clinical-stage, precision oncology company developing transformational targeted therapies for patients with cancer. We have built proprietary and ...

We look forward to leveraging the great work of the Scorpion team to date, along with Lilly's deep expertise in breast cancer, to further advance STX-478 with speed and focus." Under the terms of the ...